Octreotide for acromegaly

Authors: Cozzi, Renato; Attanasio, Roberto

Source: Expert Review of Endocrinology and Metabolism, Volume 2, Number 2, March 2007 , pp. 129-145(17)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance. Safe growth hormone and normal insulin-like growth factor I values are reached in 50-60% of unselected patients. Octreotide arrests the growth of the tumor and shrinks tumor in over half of all patients (namely, up to 88% of naive patients and to complete disappearance in anecdotic cases). The safety profile of octreotide is excellent, but in some patients, glucose metabolism worsens and cholelythiasis occurs. This review will address the primary treatment and the relative roles of pharmacological and surgical treatment, as well as the predictivity of octreotide results.

Keywords: acromegaly; growth hormone; insulin-like growth factor-I; octreotide; somatostatin analogue; tumor size

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17446651.2.2.129

Publication date: 2007-03-01

More about this publication?

Expert Review of Endocrinology & Metabolism provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites